Drug Profile

IMP 731

Alternative Names: GSK 2831781; GSK‘781; ImmuTune-IMP731; IMP-731

Latest Information Update: 20 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immutep
Developer GSK
Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
Mechanism of Action Cytotoxic T lymphocyte inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Ulcerative colitis
Phase I Plaque psoriasis

Most Recent Events

30 May 2024 GlaxoSmithKline terminates its license for IMP 731 (Immutep pipeline, January 2025)
07 May 2024 Immutep and GSK plans to terminate licensing agreement for IMP 731 in May 2024 (Immutep pipeline; May 2024)
07 May 2024 GSK 2831781 is still in phase-I trials for Plaque psoriasis in United kingdom and Germany (Immutep pipeline; May 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com